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Epicutaneous immunization is a potential non-invasive technique for antigen-specific immune-modulation. Topical application
of protein antigens to barrier-disrupted skin induces potent antigen-specific immunity with a strong Th2-bias. In this study, we
investigate whether the autoimmune inflammatory response of chronic collagen-induced arthritis (CCIA) in DBA/1-TCR-b Tg
mice can be modified by epicutaneous immunization. We show that epicutaneous immunization with type II collagen (CII)
inhibited development and progression of CCIA and, importantly, also ameliorated ongoing disease as indicated by clinical
scores of disease severity, paw swelling and joints histology. Treated mice show reduced CII-driven T cell proliferation and IFN-
c production, as well as significantly lower levels of CII-specific IgG2a serum antibodies. In contrast, CII-driven IL-4 production
and IgE antibody levels were increased consistent with skewing of the CII response from Th1 to Th2 in treated mice. IL-4
production in treated mice was inversely correlated with disease severity. Moreover, T cells from treated mice inhibited
proliferation and IFN-c production by T cells from CCIA mice, suggesting induction of regulatory T cells that actively inhibit
effector responses in arthritic mice. The levels of CD4
+CD25
+ T cells were however not increased following epicutaneous CII
treatment. Together, these results suggest that epicutaneous immunization may be used as an immune-modulating procedure
to actively re-programme pathogenic Th1 responses, and could have potential as a novel specific and simple treatment for
chronic autoimmune inflammatory diseases such as rheumatoid arthritis.
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INTRODUCTION
The route of antigen administration is a key factor in determining
the nature of an immune response. The different responses
obtained may enable alternative routes of antigen delivery to be
used for generating therapeutic immune responses. In recent
years, it has become clear that application of antigen onto bare
skin induces potent systemic and mucosal immunity in an antigen-
specific manner [1–3]. Several strategies to exploit the immune
system of the skin for needle-free vaccine delivery are currently
being developed [4,5]. These new strategies rely however on the
use of strong non-specific adjuvants for induction of good immune
responses, some of which are toxic and generally not acceptable
for human immunization. We have recently shown that a natural
adjuvant effect can be achieved by simply disrupting the stratum
corneum of the epidermis prior to topical antigen application [1].
This activates the resident Langerhans cells and negates the need
for coapplication of potentially noxious adjuvants. We have shown
previously that epicutaneous immunization on barrier-disrupted
skin induces potent and strongly Th2-biased immunity [1,6]. This
is consistent with other studies showing that the epicutaneous
microenvironment appears to naturally favour the induction of
Th2 and generally anti-inflammatory responses [2,3,7]. Further-
more, we have shown that the Th2 response induced by
epicutaneous immunization exerts a dominant effect over CFA-
induced Th1 responses by interfering with the development of
systemic antigen-specific Th1 responses and skewing established
Th1 responses towards Th2 [6]. These observations suggest that
this route of antigen delivery could be of potential therapeutic
benefit in Th1-type autoimmune diseases such as rheumatoid
arthritis (RA).
RA is an autoimmune disease characterized by chronic inflam-
mation, cyclic progressive evolution and ensuing destruction of
cartilage and bone, leading to severe disability. The disease has
a prevalence of 1%, making RA one of the most common chronic
inflammatory diseases [8,9]. In spite of intense research, many of
the principles behind the pathogenic mechanisms of RA still
remain to be elucidated. However, cumulative evidence suggests
that CD4
+ T lymphocytes predominantly expressing a Th1
cytokine pattern drives the pathology [10,11]. Joint-specific
autoantigens, such as type II collagen (CII) are thought to play
a key role by instigating T cell mediated immune responses [12]
with autoantibodies subsequently also being involved [8]. Several
therapeutic strategies are available for RA and continuous
improvement and refinement of these therapies have had a pro-
found impact on progression of disease and quality of life for RA
patients [13]. None of the currently used therapies are, however,
disease- or antigen-specific and there is therefore a need for
developing new disease-specific therapies which may benefit RA
patients.
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PLoS ONE | www.plosone.org 1 April 2007 | Issue 4 | e387DBA/1-TCR-b Tg mice develop a chronic relapsing poly-
arthritis with an incidence approaching 100% after immunization
with CII in CFA. This model of chronic collagen-induced arthritis
(CCIA) is dependent on CD4
+ Th1 cells and shares key
characteristics with human RA [12]. In this study, we use the
CCIA model to investigate the potential of epicutaneous
immunization to provide a means of modulating RA. We report,
that epicutaneous immunization with CII protects against the
development of CCIA and importantly is also effective in
ameliorating disease when given after induction of CCIA.
Epicutaneous immunization, whether prior or post induction of
disease, inhibits pathogenic CII-driven Th1 responses and
enhances anti-inflammatory Th2 responses. These results suggest,
that this route of active autoantigen immunization may provide an
alternative or complimentary therapeutic strategy for autoimmune
diseases such as RA.
RESULTS
Epicutaneous immunization with CII inhibits
development of CCIA
Topical application of protein antigen to skin from which the
stratum corneum has been removed with adhesive tape gives rise
to potent systemic immune responses [1]. Immunity initiated via
such epicutaneous immunization is strongly Th2-biased with high
levels of antigen-specific IgG1 and IgE and enhanced production
of IL-4 but with little or no IgG2a and IFN-c [1]. The Th2
responses obtained by this route are dominant over Th1 responses
induced by antigen in CFA [6], suggesting that epicutaneous
immunization with an RA autoantigen could modulate disease in
the CCIA model. To examine this possibility, DBA/1-TCR-b Tg
mice were immunized epicutaneously with CII three weeks prior
to induction of arthritis. Development of clinical disease was
closely monitored for five weeks following arthritis induction
(Figure 1). A highly significant decrease in disease severity as well
as a delay in the onset and an overall lower incidence of disease
was observed in treated mice compared to sham treated CCIA
diseased controls. The treated mice that did show disease
developed a milder arthritis (p,0.0001) (Figure 1A) with reduced
paw swelling (p,0.0001) (Figure 1B) and with fewer joints
involved (p,0.0001) (data not shown). These results demonstrated
a highly significant effect of epicutaneous immunization on both
the incidence and evolution of clinical arthritis.
Histological features
Hind paws were collected at the end of the experiment and joints
evaluated histologically to determine whether the amelioration of
disease in the treated mice correlated with reduced joint damage
(Figure 2A). Sections of hind paws from healthy control animals
showed open joint spaces free of cells, bones were closely apposed
with smooth surfaces of bone and cartilage and no inflammatory
cellular infiltrates were visible. Diseased CCIA mice had an
extensive inflammatory infiltrate in the joint spaces, contours of
bone and cartilage were irregular and in most cases there was
severe pannus invasion. Pannus extended over the articular
cartilage, eroded the junction of the cartilage and bone and in
many cases expanded into the bone marrow space. In these
severely diseased CCIA mice there was a complete loss of bone
architecture with a collapse of the joint and extensive bone
erosion. In sharp contrast, most of the joint sections from mice
treated by prior epicutaneous immunization with CII showed no
signs of inflammation, synovitis or any affect on cartilage or bone.
Surfaces of bone and cartilage were in most cases smooth and
bone architecture appeared normal. Some treated mice did show
joint damage with some inflammatory infiltrate and erosion of
cartilage, but these cases were much milder than the majority of
CCIA control mice and bone architecture was never completely
lost (Figure 2A). To obtain a quantitative measure of the effect
of treatment on histopathology, sections of both hind paws of
all mice were scored for the severity of joint damage, extent of
inflammation and bone erosion using an arbitrary scale by
independent investigators ‘blinded’ to mouse identity. The analysis
showed that the histopathology of joints from treated mice were
significantly milder than in sham-treated control mice (p,0.003).
10/18 joints from treated mice showed no signs of pathology
whereas the rest showed varying degrees of inflammatory infiltrate
and cartilage erosion. None however showed severe bone
destruction with complete loss of bone architecture (Figure 2B).
These results illustrate the potent suppressive effect of epicuta-
neous immunization on the inflammatory processes leading to
joint destruction.
Figure 1. Epicutaneous immunization prevents evolution of arthritis.
DBA/1-TCR-b Tg mice were epicutaneously immunized with CII 3 weeks
prior to induction of disease by injection of CII in CFA. Mice were
evaluated and clinical score (A) and hind paw thickness (B) were
assessed every second day. Data represents the mean+1 SEM (n=9).
The epicutaneous immunization had a highly significant effect on
disease severity as analysed by two-way ANOVA. The entire in vivo
experiment was repeated twice with very similar results. ($)=treated
with epicutaneous CII, (m)=sham-treated CCIA controls.
doi:10.1371/journal.pone.0000387.g001
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proliferation and skews the pathogenic CII Th1
response to a Th2 response
Our previous studies have shown that the epicutaneous immuni-
zation procedure used here induces a potent Th2 response that is
able to override an ongoing Th1 response [1,6], suggesting that
this may be the mechanism responsible for the effect on clinical
CCIA shown above. To examine this hypothesis, splenocytes were
collected from all animals at the end of the experiment and CII-
driven T cell proliferation as well as cytokine release were deter-
mined. In both the CCIA arthritic and treated groups, dose-
dependent proliferation of splenic T cells was demonstrated to
CII but not to control antigen, while T cells from healthy (un-
immunized) mice only proliferated marginally above background
when stimulated with CII (Figure 3A). The response of T cells
from treated mice was however significantly reduced compared
to T cells from sham-treated CCIA arthritic mice (Figure 3A). The
CII-driven proliferation by T cells from treated mice was con-
sistently about 60% lower than for T cells from CCIA mice,
regardless of the CII concentration used. Cytokines produced by
CII activated T cells from the experimental groups were also
determined (Figure 3B). High levels of IFN-c and low levels of IL-4
were secreted by splenocytes from CCIA diseased mice in response
to CII stimulation. In contrast, IFN-c production was significantly
reduced in treated animals (p,0.01). This decrease in IFN-c was
mirrored by a concomitant and significant increase in IL-4
(p,0.01) and to a lesser extent IL-13 production (p=0.07). The
level of CII-driven IL-4 production in both groups of animals
demonstrated a significant inverse linear correlation with disease
severity (Figure 4A). Conversely, production of IFN-c showed
a positive linear correlation to the severity of arthritis, with treated
animals producing the lowest amount of IFN-c (Figure 4B).
Similar levels of CII-driven IL-10 and TGF-b were induced in the
two groups (Figure 3B). The levels of cytokines produced when
splenocytes from healthy mice were stimulated with CII were
below (IL-4) or only just over the detection limit of the assays
(Figure 3B). No cytokines were produced to a control antigen or
when cells were not stimulated (data not shown).
CII-specific serum antibodies are reduced by
epicutaneous immunization
To determine whether epicutaneous immunization affected anti-
body responses to CII in CCIA diseased mice, levels of CII-specific
IgG, IgG1 and IgG2a in sera were measured (Figure 5). The
Figure 2. Histopathological damage of joints is reduced following epicutaneous immunization. Hind paws from healthy mice, CCIA control mice
and epicutaneously treated mice were sectioned and stained with H&E (A). One representative example is shown. Note that skin and muscle remain
unaffected in CCIA mice. Histological sections were evaluated and arbitrary scores assigned in 5 categories (4 being the most severe score) for extent
of inflammatory infiltrate, cartilage and bone erosion. The number of affected hind paws assigned each severity score is shown (B). The mean
histopathological severity score was significantly lower in treated mice, p,0.003 (n=18). Healthy=un-CFA-immunized non-arthritic littermate, CCIA
(&)=sham-treated arthritic mouse, Treated (&)=epicutaneously immunized mouse.
doi:10.1371/journal.pone.0000387.g002
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PLoS ONE | www.plosone.org 3 April 2007 | Issue 4 | e387Figure 3. Epicutaneous immunization inhibits CII-specific proliferation, reduces Th1 and enhances Th2-type cytokines. Splenocytes were
collected from each mouse and cultured for 90 h with CII or control antigen. Proliferation was determined by [
3H]-thymidine incorporation (A) and
cytokine production by ELISA (B). Results of proliferative experiments are expressed as mean cpm+1 SEM (n=9). Background proliferation when no
antigen was present has been subtracted. No proliferation was observed to control antigen but the two groups responded with similar [cpm] when
stimulated with ConA. Production of IFN-c, IL-4, IL-13, IL-10 and TGF-b is expressed as mean pg/ml+1 SEM (n=9). No cytokines were produced in
response to a control antigen or when cells were not stimulated. Dashed horizontal lines (where visible) represents limit of detection. (%)=un-
immunized healthy controls, (&)=treated with epicutaneous CII, (&)=sham-treated CCIA controls.
doi:10.1371/journal.pone.0000387.g003
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specific IgG2a compared to CCIA arthritic mice (p,0.01) and this
was mirrored by reduced CII-specific IgG (p,0.05) levels (Figure 5).
The epicutaneous immunization had no significant effect on CII-
specific IgG1. To further test whether the epicutaneous immuniza-
tionhadinducedashiftinthenatureofTcellhelp,levelsofIgEwere
testedinthe sera. Notably,the leveloftotal IgEwas greatlyincreased
in the treated mice (p,0.0001). These results are consistent with the
observed Th2 skewing of cytokine production and suggest that the
epicutaneous immunization treatment restrained the widely recog-
nized pathogenicTh1 CII specificresponsewith a partial redirection
towards a Th2 response.
Lymphocytes from treated mice inhibit responses of
T cells from CCIA arthritic mice
Epicutaneous immunization inhibited T cell proliferation to CII in
treated mice as shown in Figure 3. We therefore considered the
possibility that epicutaneous immunization may generate T cells
that can inhibit the effector function of T cells from mice with
CCIA. To examine this possibility, T cells from CCIA and treated
mice were cocultured at various cell ratios and the proliferative
response to CII stimulation was measured. The results showed that
CII-driven proliferation by splenocytes from CCIA mice was
inhibited when cocultured with splenocytes from treated mice
(Figure 6A). Introducing as few as 10% of cells from treated mice
into the cultures of cells from CCIA mice reduced the proliferative
response to about half of that predicted from responses by cells
from both groups of animals cultured alone. In addition, secretion
of IFN-c by cells from CCIA mice was completely inhibited by
coculture with treated cells (p,0.05). Levels of IFN-c were signifi-
cantly below the levels expected from the cells cultured separately.
Simultaneously, IL-4 was increased (p,0.02) but only to the
predicted level (Figure 6B). No inhibitory effect was observed on
proliferation or cytokine secretion when cells from two CCIA
control mice were cocultured (data not shown). Nor was any
inhibitory effect observed when the cells were stimulated with the
mitogen Concanavalin A (ConA) (not shown), suggesting that
inhibition was specific for the CII response.
There is good evidence that the CD4
+CD25
+ T cell subset
(natural T regulatory cells) can confer protection in a variety of
autoimmune disease models [14–16]. We therefore analysed
whether a difference in the relative proportion of CD4
+CD25
+ T
cells could beresponsible forthereduced proliferation andinhibitory
effect of T cells from epicutaneously treated mice. Splenocytes were
stained for CD4
+ and CD25
+ T cells and analysed by flow cyto-
metry. There were no differences in the proportion of CD4
+CD25
+
T cells from CCIA diseased mice and treated mice in either freshly
isolatedsplenocytes (Figure 6C)orfollowing 90 hre-stimulation with
CII (Figure 6D). In previous experiments we had additionally
demonstrated that there was no difference in the expression level of
FoxP3 or Glucocorticoid-induced TNF receptor family related
protein (GITR) between diseased CCIA and healthy un-immunized
mice as assessed by flow cytometry (data not shown), therefore these
markers of (natural) regulatory T cell function were not further
evaluated in the experiments shown here.
Treatment by epicutaneous immunization after
induction of CCIA ameliorates arthritis
The results so far show that prior epicutaneous immunization with
CII profoundly inhibits CCIA induced three weeks later with CII
in CFA. In order to investigate whether this form of treatment can
Figure 4. CII-driven production of IL-4 correlates inversely with
severity of arthritis. The linear correlation between Th2/Th1 cytokine
production and severity of arthritis following epicutaneous immuniza-
tion was analysed using linear regression. Production of IL-4 was
negatively correlated to the clinical score (A) while production of IFN-c
was positively correlated to clinical score (B). Each point represents one
mouse. ($)=treated with epicutaneous CII, (m)=sham-treated CCIA
controls.
doi:10.1371/journal.pone.0000387.g004
Figure 5. Epicutaneous immunization inhibits development of CII-
specific IgG2a and IgG. CII-specific IgG, IgG1 and IgG2a as well as total
IgE were measured in serum at the end of the experiment. Serum
samples were diluted 1:1500 for IgG, IgG1 and IgG2a and 1:20 for IgE
prior to analysis. Each bar represent mean antibody level+1 SEM (n=9).
(&)=treated with epicutaneous CII, (&)=sham-treated CCIA controls.
doi:10.1371/journal.pone.0000387.g005
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DBA/1-TCR-b Tg mice were subjected to epicutaneous CII
immunization one week after induction of disease by intradermal
injection of CII in CFA. In these experiments there were no
difference in the time of disease onset in the two groups but the
progression and overall clinical severity of CCIA was significantly
reduced in the group treated by epicutaneous CII immunization
(p,0.0001) (Figure 7A). The significant reduction in arthritic
Figure 6. Lymphocytes from epicutaneously immunized mice inhibit
proliferation and IFN-c production by lymphocytes from CCIA mice.
Splenocytes from a sham-treated CCIA control were cocultured with
splenocytes from an epicutaneously treated mouse at varying ratios (A).
Total number of cells in the culture was kept constant. Cocultures were
stimulated with 50 mg CII/ml and CII-specific splenocyte proliferation
was assayed as in Figure 3. Black bars demonstrate the expected
proliferation [cpm] in the culture, calculated by the formula: [cpm]=a
f+b(12f), where a=[cpm] with 100% control cells, b=[cpm] with 100%
treated cells, f=fraction of control cells in the culture. The observed
r
[
3H]-thymidine incorporation is shown in white bars and represents the
mean of triplicate cultures. Similar results were obtained in four
individual experiments. Production of IFN-c and IL-4 in 1:1 ratio
cocultures of splenocytes from control and treated mice were assessed
by ELISA and results are expressed as mean pg/ml+1 SEM (n=4) (B). No
cytokines were produced in response to a control antigen or when cells
were not stimulated. The proportion of CD4
+CD25
+ T cells in freshly
isolated splenocytes (C) from CCIA control or epicutaneously immu-
nized mice and after 90 h in vitro stimulation with 50 mg CII/ml (D) were
assessed by flow cytometry. Results are expressed as the mean [%]
CD4
+CD25
+ T cells out of the total CD4
+ population+1 SEM (n=9).
(&)=treated with epicutaneous CII, (&)=sham-treated CCIA controls.
doi:10.1371/journal.pone.0000387.g006
Figure 7. Treatment with epicutaneous immunization ameliorate
ongoing arthritis. Arthritis were induced in Tg mice by injection of CII
in CFA and 1 week later mice were treated with epicutaneous CII. Mice
were evaluated and clinical score (A) and hind paw thickness (B) were
assessed every second day for 49 days. Data represents the mean+1
SEM (n=9). Treatment by epicutaneous immunization had a significant
effect on disease severity as analysed by two-way ANOVA. ($)=treated
with epicutaneous CII, (m)=sham-treated CCIA controls.
doi:10.1371/journal.pone.0000387.g007
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(Figure 7B) and the involvement of fewer joints (p,0.05) (not
shown) compared to sham-treated CCIA controls.
Splenocytes collected from mice treated by epicutaneous CII
after induction of CCIA also exhibited reduced dose-dependent T
cell proliferation to CII stimulation compared to T cells from
sham-treated CCIA mice (Figure 8A). In addition, the production of
pathogenic IFN-c in response to CII stimulation was significantly
inhibited in treated mice (p,0.005) (Figure 8B) whereas IL-4 was
significantly increased (p,0.05). The production of IL-13 was also
consistently increased in treated mice, although this did not reach
statistical significance. There was no significant difference inthe CII-
driven production of IL-10 or TGF-b between treated and non-
treated mice (Figure 8B). Splenic T cells from healthy control mice
showedonlymarginalTcellproliferationandcytokineproductionin
response to CII stimulation (Figure 8).
Figure 8. Treatment with epicutaneous immunization reduces CII-driven proliferation and IFN-c production while IL-4 production is enhanced.
Splenocytes were collected from all mice on day 49 after induction of disease and cultured with CII or control antigen for 90 h. CII-driven proliferation
(A) and production of IFN-c, IL-4, IL-13, IL-10 and TGF-b (B) were assayed as described in Figure 3. Results are expressed as mean+1 SEM (n=9).
(%)=un-immunized healthy controls, (&)=treated with epicutaneous CII, (&)=sham-treated CCIA controls.
doi:10.1371/journal.pone.0000387.g008
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were also measured 42 days after epicutaneous immunization (i.e.
49 days after induction of CCIA). Treated mice had significantly
lower levels of anti-CII IgG2a (p,0.05) compared to CCIA
controls (Figure 9). The total level of anti-CII IgG was also signifi-
cantly reduced (p,0.05), presumably as a consequence of the
reduced CII-specific IgG2a levels. Epicutaneous immunization
had no effect on levels of CII-specific IgG1 but levels of total IgE
were increased (p,0.05) (Figure 9). Treatment by epicutaneous
CII immunization after induction of CCIA had thus caused
a modulation of the anti-CII antibody response, resulting in
a decrease in the ratio of IgG2a to IgG1 and a reduction in the
levels of complement-fixing antibodies, consistent with a Th2 skew.
DISCUSSION
Epicutaneous immunization with protein or peptide antigens
without adjuvants can induce a sustained Th2-type response that is
able to skew an ongoing Th1 response towards Th2 as indicated
by cytokine production and antibody response [1–3,6]. In this
study, we sought to utilise this route of immunization with CII to
interfere with the development and evolution of CCIA disease in
the DBA/1-TCR-b Tg mouse model of RA. RA has a number of
systemic manifestations but it is the chronic inflammation in the
joints that is the most prominent and consistently destructive
feature of the disease [9]. There is compelling evidence that T cells
are central in many autoimmune diseases, though complex inter-
actions with other immuno competent cells are often required and
necessary for the full profile of the disease. A number of studies
have suggested that T cells in RA joints are predominantly of the
Th1 phenotype [10,13] and there is general consensus that a Th1
pro-inflammatory response initiates the whole pathogenic cascade.
On that basis, it has been suggested that down-regulation of the
Th1 response in RA could be beneficial for preventing the clinical
progression of disease. We have shown here that epicutaneous
immunization with CII significantly interferes with the develop-
ment of CCIA. The incidence of disease was reduced in treated
mice and when disease developed it showed a delayed onset and
both the clinical phenotype and the pathological destruction of the
bone were considerably milder than in control mice. Immunolog-
ically, epicutaneous immunization inhibited the development of
CII-specific pathogenic Th1 responses by significantly reducing
IFN-c and IgG2a. Simultaneously, this route of CII administration
induced active Th2 responses by enhancing CII-specific IL-4 and
IL-13 and increasing levels of IgE. Importantly, a similar reduction
in disease severity and intensity of CII-specific Th1 responses were
observed when epicutaneous CII was administered after induction
of disease. Again a significant skew from Th1 to Th2 immunity
was apparent in cytokine production and IgG isotype. Moreover,
disease severity was directly correlated with IFN-c production and
inversely correlated with levels of CII-induced IL-4 production.
Together, these results suggests that epicutaneous immunization is
effective in controlling arthritis by actively inhibiting autoantigenic
and pathogenic Th1 responses and promoting specific anti-
inflammatory Th2 responses. Even more effective inhibition of
disease may be possible by repeated epicutaneous immunizations
and further studies will address this possibility.
Recently, a subset of IL-17 producing T helper cells (Th17) dis-
tinct from Th1 and Th2 cells have been described [17,18]. IL-17
appears to play a major role in several models of immune-
mediated tissue injury, including organ-specific autoimmunity
such as rheumatoid arthritis. Collagen-induced arthritis is sup-
pressed in IL-17
-/- mice [19] and Th17 cells are involved in bone
destruction and remodelling [20]. In this study we have focused on
Th1 cells but further studies will identify whether the disease
controlling effects of epicutaneous immunization on CCIA is
additionally caused by an effect on Th17 cells.
Beneficial effects on the development of RA by inhibiting Th1
or enhancing Th2 responses have been demonstrated in previous
studies. For example, neutralization of IFN-c or IL-12 [21,22] or
administration of IL-4 [23] during the early phase of disease has
been shown to exert a protective effect on the evolution of arthritis,
although these strategies were less effective or ineffective if admi-
nistered during established disease. In human RA, inhibition of
pro-inflammatory cytokines such as IL-1b [24,25] and notably
TNF-a [13,26] has proven effective in modifying disease and has
profoundly improved the quality of life for some patients with
severe RA. However, while it is possible to temporally down-
regulate the Th1 response by passively blocking Th1-type
cytokines or by administering Th2-type cytokines, the response
reverts back to a Th1 response once treatment is stopped [23]. In
this study, we sought to use a different strategy by inducing active
Th2 responses through epicutaneous immunization for treatment
of Th1-mediated arthritis. By actively immunizing through this
route, self-sustainable clones of Th2 cells with a broader range of
Th2 cytokine expression and subsequent continued Th2 help can
be induced. Of major importance is the antigen-specificity of the
active Th2 responses induced by epicutaneous immunization [6].
This should promote selective migration of CII-specific Th2 cells
to the diseased tissue where they can exert their effect. At the site
of disease activity they may also suppress pathogenic responses to
other joint antigens by way of local bystander suppression, a
phenomenon that has been demonstrated in several animal models
of inflammatory autoimmune disease [27,28]. Bystander suppres-
sion has also been reported in vitro in humans [29] but little is
known about whether this occurs in vivo in humans or how it can
be triggered. Another obvious advantage of inducing antigen-
specific therapeutic responses is that Th1 responses to other
antigens and pathogens such as mycobacterium should not be
suppressed, which reduces the problematic augmented risk of
infection that a non-specific approach carries [13].
Several mechanisms could be behind the inhibitory effect of
epicutaneous immunization on pathogenic Th1 responses and
disease severity. The observed overall switch from Th1 to Th2-
type immunity may represent the de novo induction of a dominant
antigen-specific Th2 population or may be due to an actual
reversal in differentiation commitment of the CII-specific Th cells.
Differentiation of Th1 and Th2 cells are strongly influenced by the
Figure 9. Treatment with epicutaneous immunization reduces levels
of CII-specific IgG2a and IgG. CII-specific IgG, IgG1 and IgG2a as well as
total IgE were measured in serum at the end of the experiment. Serum
samples were diluted 1:1500 for IgG, IgG1 and IgG2a and 1:20 for IgE
prior to analysis. Each bar represent mean antibody level+1 SEM (n=9).
(&)=treated with epicutaneous CII, (&)=sham-treated CCIA controls.
doi:10.1371/journal.pone.0000387.g009
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transcription factors T-bet [30] and GATA-3 [31]. T cell differ-
entiation at a population level ultimately depends on the expression
dynamics of T-bet and GATA-3, which are mutually exclusive [32].
It is theoretically possible to reverse Th cell commitment through
manipulation of these transcription factors by IFN-c and IL-4 [32].
Although this remains an exciting hypothetical possibility, it is not
possible to determine from the experiments described here whether
the switch to a Th2 dominant response following epicutaneous
immunization represents a true re-programming of CII specific T
cells or preferential expansion of Th2 T cells.
Another possible mechanism behind the distinct change in the
Th cell profile after epicutaneous immunization is active
suppression of the ongoing Th1 response allowing for emergence
of Th2 cells. Our data suggests that epicutaneous immunization
not only produces an immunological switch from Th1 to Th2 but
may also trigger a suppressive/regulatory pathway. In cocultures,
cells from mice treated by epicutaneously immunization were able
to actively inhibit CII-specific proliferation and IFN-c release by
effector cells, suggesting an active regulatory mechanism. Adding
as little as 10% of cells from treated mice to cultures of cells from
diseased CCIA mice completely inhibited IFN-c production,
showing the dominant suppressive effect of the epicutaneously
induced T cells. We did not however detect an increase in the
proportion of CD4
+CD25
+ T cells in treated mice, which may
suggest that the induced suppressive effect does not involve the
naturally occurring CD4
+CD25
+ regulatory T cell population.
This is consistent with observations from several other populations
of peripherally- and antigen-induced regulatory T cells that do not
express CD25 or FoxP3 [33,34]. However, it can not from our
experiments be excluded that naturally occurring CD4
+CD25
+
regulatory T cells are responsible for the observed suppressive
effect in epicutaneously immunized mice and this needs to be
examined further. Epicutaneous immunization with autoantigens
has previously been shown able to induce a suppressive/regulatory
response, which prevented development of EAE [35]. The disease
resistance was shown to be mediated by CD4
+ suppressor T cells
but was not dependent on CD4
+CD25
+ T cells. The therapeutic
potential of these cells on established disease was not determined.
Interestingly, other recent studies have confirmed that epicuta-
neous immunization may induce immune-regulatory networks
with potential therapeutic advantages [36,37]. This is an intriguing
possibility, but whether the skin-induced CII-specific T cells are
truly suppressive when transferred into arthritic mice has yet to be
tested in our model.
Extrapolation from animal models to human disease requires
great caution, but if the apparent Th2 skewing of the response
following epicutaneous immunization holds true in humans, its
use as therapy for chronic Th1-driven pathologies would have
obvious advantages. Epicutaneous immunization is simple,
painless, economical and would allow for (repetitive) self-
administration. Further studies elucidating the mechanisms behind
skin-induced systemic immune responses and experiments in
humans should now be instigated.
In conclusion, we have shown that epicutaneous immunization
can successfully control a chronic inflammatory autoimmune
process, highlighting its potential future use in patients suffering
from RA or other autoimmune disorders.
MATERIALS AND METHODS
Mice
Heterozygous TCR-b transgenic SWR/J mice were extensively
backcrossed with DBA/1 mice to derive the chronic collagen-
induced arthritis model, as described previously [12,38]. Mice
were typed for TCR-b Tg expression by FACS and the Tg positive
mice selected for experiments. Over 96% of peripheral blood T
cells in Tg mice were Vb12
+. Male mice aged 6–8 weeks were used
in this study in accordance with Home Office regulations under
the Animals (Scientific Procedures) Act 1986.
Antigens
Bovine collagen type II (CII) was purified and prepared as
described [39]. In brief, for immunization, the CII was solubilized
by stirring overnight at 4uC in 0.1 M acetic acid. For in vitro
stimulation, CII was solubilized in 0.05 mM Tris-HCL and 0.2 M
NaCl at pH 7.4.
Induction and assessment of arthritis
Male DBA/1-TCR-b Tg mice were immunised with 200 mg CII
emulsified in CFA by intradermal injection at the base of the tail.
Mice were monitored daily and analysed every second day after
the onset of clinical disease. The number of affected joints, clinical
severity score and hind paw swelling were recorded by two
investigators ‘blinded’ to mouse identity for the duration of each
experiment. The clinical severity of arthritis was graded as follows:
0=normal, 1=slight swelling and/or erythema, 2=pronounced
edematous swelling, 3=pronounced edematous swelling plus joint
rigidity, 4=laxity. Each limb was graded, allowing a maximum
score of 16 for each animal. Swelling of hind paws was measured
using a microcaliper (Mitutoyo, Siwa, Japan).
Epicutaneous immunization
Mice were epicutaneously immunized with CII either 3 weeks
prior or 1 week post induction of arthritis. CII used for this
immunization was solubilized in acetic acid but just prior to
application pH was raised to 5.2 with TRIS-HCl. For epicuta-
neous immunization, the stratum corneum was removed from
both sides of the earlobe by gentle application and removal of
cellophane tape (Scotch
TM (3M, Cergy-Pontoise Cedex, France))
as described [1]. Twenty-four hours later, 50 mg CII were applied
to both sides of the earlobe. The application of CII to the skin was
repeated on the next two consecutive days. Control animals had
acetic acid/TRIS-HCl without CII applied to stripped skin in an
identical manner. Two weeks after the initial epicutaneous
immunization a boost was given by a single application of 50 mg
CII on de novo stripped ear skin.
Histological evaluation
Hind paws were removed post mortem and fixed in 10% (weight/
volume) buffered formalin and decalcified in 5% EDTA. The
paws were subsequently embedded in paraffin, sectioned and
stained with haematoxylin and eosin (H&E) for microscopic
evaluation. Histological sections were scored for severity of
pathological changes by two investigators ‘blinded’ to sample
identity. The severity of arthritis was scored based on the following
criteria: 0=normal, 1=minimal synovitis and cartilage loss, no
bone erosion, 2=synovitis and erosion present but limited to
discrete foci and joint architecture intact, 3=moderate synovitis
with pannus formation and erosion of cartilage and bone,
4=severe inflammation with extensive erosion of bone and
cartilage and loss of joint architecture.
T cell proliferation and co-cultures
Spleen cell suspensions were obtained from every mouse by
mechanical disaggregation and lysis of red blood cells. Splenocytes
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5 cells in 96-well flat-bottom plates in a total
volume of 200 ml RPMI 1640 medium supplemented with 10%
FCS, 50 mM 2-mercaptoethanol and 5 mg/ml gentamycin. CII
was added at concentrations of 50 mg/ml or 10 mg/ml. Control
responses to an irrelevant antigen (OVA) at 50 mg/ml, ConA at
1 mg/ml or media alone were also determined. Cultures were
incubated at 37uC for 90 h and pulsed with 1 mCi of [
3H]-
thymidine (Amersham Pharmacia, Little Chalfont, UK) for the last
16 h. Cells were harvested and thymidine incorporation de-
termined by liquid scintillation counting on a MicroBeta (Wallac,
Turku, Finland).
To determine whether cells from epicutaneously treated mice
could suppress CII-specific proliferation of control cells, spleno-
cytes from control and treated mice were co-cultured by varying
the ratio between the cells in culture, while keeping the overall cell
density constant at 3610
5 cells/well. Splenocytes from control and
treated mice were cultured in ratios of 10:0, 10:1, 10:5, 1:1, 5:10,
1:10 and 0:10. The cultures were stimulated with 50 mgo r1 0mg
CII/ml, 50 mg OVA/ml, 1 mg ConA/ml or left unstimulated for
90 h at 37uC. Cells were then pulsed with [
3H]-thymidine,
harvested and counted as described above.
Flow cytometry
Freshly isolated splenocytes from all mice were stained for CD4
and CD25 using antibodies from PharMingen (San Diego, CA,
USA) (clone GK1.5 and clone 7D4 respectively). Cells were
incubated with a saturating concentration of the two antibodies or
isotype controls for 30 min at 4uC in the dark. The cells were then
thoroughly washed and fixed in 1% paraformaldehyde. Spleno-
cytes from all mice were also stained for CD4
+CD25
+ cells
following 90 h stimulation with 50 mg CII/ml in an identical
manner. All cells were analyzed for two-colour cytometry staining
on a FACScalibur instrument (Becton Dickinson, Mountain View,
CA) and data analysis was performed with CellQuest software
(Becton Dickinson). Viable lymphocytes were gated based on their
forward/side scatter profile, after which CD4
+CD25
+ cells were
gated based on expression on CD4 and CD25.
Cytokine production
3610
6 splenocytes were cultured in 1 ml RPMI 1640 medium
supplemented with 10% FCS, 50 mM 2-mercaptoethanol and
5 mg/ml gentamycin in 24-well tissue culture plates (Nunc,
Roskilde, Denmark). Cells were stimulated with 50 mg CII/ml,
50 mg OVA/ml or left unstimulated for 90 h at 37uC. Culture
supernatants were collected and subsequently assayed by ELISA
for IFN-c, IL-4, IL-10 and TGF-b using antibodies from
PharMingen, according to the manufacturer’s protocol. Recombi-
nant mouse IFN-c, IL-4, and IL-10 and human TGF-b from
PharMingen were used as standards. The detection limit of the
assays was 3 pg/ml for IL-4 and 40 pg/ml for IFN-c, IL-10 and
TGF-b. Supernatants were assayed for IL-13 using mouse IL-13
Quantikine ELISA kit from R&D Systems (Minneapolis, MN,
USA). Detection limit for IL-13 was 8 pg/ml.
Antibody responses
At the end of each experiment, mice were bled by cardiac
puncture and sera prepared for CII-specific antibody determina-
tions. For IgG, IgG1 and IgG2a antibodies, 96-well Maxisorb
plates (Nunc) were coated with CII at 100 mg/ml in carbonate-
bicarbonate buffer at 4uC over night. Optimally diluted sera
(100 ml in PBS) were added and the plates incubated at 37uC for
90 min. After washing, alkaline phosphatase conjugated poly-
clonal goat anti-mouse IgG Fc (Sigma, Gillingham, UK), rat
monoclonal antibody to mouse IgG1 (Zymed, San Francisco, CA,
USA) or rat monoclonal antibody to IgG2a (PharMingen) were
added for 1 h at 37uC. The alkaline phosphatase substrate pNPP
(Sigma) was then added and absorbance measured at 405 nm.
Total IgE was measured by an IgE capture method. Sera to be
tested were added to Maxisorb microtiter plate wells coated with
rat monoclonal anti-mouse IgE (PharMingen) at 1 mg/ml and
incubated at 4uC overnight. Biotin conjugated monoclonal rat
anti-mouse IgE (PharMingen) was then added at 1 mg/ml and
incubated for 2 h at 37uC. After washing, alkaline phosphatase
streptavidin (PharMingen) was added for 1 h followed by pNPP
substrate.
Statistical evaluation
The statistical significance of difference in clinical severity between
experimental groups over the entire length of the experiment was
determined by a 2 way ANOVA. Two-tailed Student’s t-test for
unpaired data was used for the other experiments. Differences
were regarded as significant when p,0.05.
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